Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.

The Editor-in-Chief is Arnold Ganser, Department of Hematology, Hemostasis and Oncology, Medizinische Hochschule Hannover.

Why publish with us

  • We are a forum for clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology.
  • We welcome articles in relevant aspects of oncology, molecular biology and immunology, and also covers diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells.
  • We provide high levels of author satisfaction, with 96% of our published authors reporting that they would definitely or probably publish with us again.

Journal information

Editor-in-Chief
  • Arnold Ganser
Publishing model
Hybrid (Transformative Journal). Learn about publishing Open Access with us

Journal metrics

2.904 (2019)
Impact factor
2.838 (2019)
Five year impact factor
51 days
Submission to first decision
125 days
Submission to acceptance
390,564 (2019)
Downloads

Latest articles

Journal updates

  • Editor's Choice Articles

    The Editor-in-Chief of Annals of Hematology acknowledges the quality of papers by choosing in each issue one article that is outstanding with respect to scientific quality and public-health relevance.

  • Research Updates on COVID-19

    We invite you to read the most recently published articles in Annals of Hematology on emerging COVID-19 research.

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

Subscribe

eJournal
$119.00
Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles starting 1997
  • Downloadable in PDF format
  • Subscription expires 12/31/2021

About this journal

Electronic ISSN
1432-0584
Print ISSN
0939-5555
Abstracted and indexed in
  1. AGRICOLA
  2. ANVUR
  3. BIOSIS
  4. Biological Abstracts
  5. CAB Abstracts
  6. CNKI
  7. Chemical Abstracts Service (CAS)
  8. Current Contents/ Life Sciences
  9. Current Contents/Clinical Medicine
  10. Dimensions
  11. EBSCO Academic Search
  12. EBSCO Biomedical Reference Collection
  13. EBSCO CINAHL
  14. EBSCO Discovery Service
  15. EBSCO STM Source
  16. EMBASE
  17. Google Scholar
  18. Institute of Scientific and Technical Information of China
  19. Japanese Science and Technology Agency (JST)
  20. Journal Citation Reports/Science Edition
  21. Medline
  22. Naver
  23. OCLC WorldCat Discovery Service
  24. Pathway Studio
  25. ProQuest Central
  26. ProQuest Health & Medical Collection
  27. ProQuest Health Research Premium Collection
  28. ProQuest Medical Database
  29. ProQuest Nursing & Allied Health Database
  30. ProQuest Pharma Collection
  31. ProQuest-ExLibris Primo
  32. ProQuest-ExLibris Summon
  33. Reaxys
  34. SCImago
  35. SCOPUS
  36. Science Citation Index
  37. Science Citation Index Expanded (SciSearch)
  38. Semantic Scholar
  39. TD Net Discovery Service
  40. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer-Verlag GmbH Germany, part of Springer Nature